Avita Medical (ASX:AVH) said its multicenter, randomized controlled clinical study for PermeaDerm, a biosynthetic wound matrix, met its primary endpoint, showing statistically significant superiority for mean cost per percent total body surface area treated, according to a Wednesday Australian bourse filing.

The study enrolled 40 patients across 11 US burn centers, with wounds of up to 30% total body surface area. After excision, patients were randomized to receive either PermeaDerm or cadaveric allograft during the temporization period before definitive split-thickness skin grafting.

Mean treatment cost was AU$148.70 for every 1% total body surface area treated with PermeaDerm, compared with AU$497.10 for allograft, representing a savings of around AU$348 per percent total body surface area.

Around 94% of patients treated with PermeaDerm achieved at least 95% graft take one week following autografting, comparable to allograft, and all patients in both groups achieved 95% or greater wound healing by eight weeks.

PermeaDerm reduced preparation time by 95.7% compared with allograft by eliminating tissue tracking, thawing, and meshing, the filing added.